GSC Biological and Pharmaceutical Sciences
eISSN: 2581-3250 CODEN (USA): GBPSC2
Cross Ref DOI: 10.30574/gscbps
Journal homepage: https://gsconlinepress.com/journals/gscbps/

(REVIEW ARTICLE)

Check for updates

Immune Modulation Through Directed Th2 Polarization: Programming Naïve T Cells to Suppress Autoimmune Pathways in Amyotrophic Lateral Sclerosis

Michael John Dochniak *

Alleamit Corporation, Minnesota, United States of America.

GSC Biological and Pharmaceutical Sciences, 2026, 34(01), 019-023

Publication history: Received on 22 November 2025; revised on 04 January 2026; accepted on 06 January 2026

Article DOI: https://doi.org/10.30574/gscbps.2026.34.1.0003

Abstract

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder characterized by motor neuron loss, neuroinflammation, and immune dysregulation. Increasing evidence demonstrates that a peripheral and central shift toward proinflammatory Th1 and Th17 immune responses correlate with disease severity and progression. In contrast, T helper type-2 (Th2)–associated immune responses exert neuroprotective and anti-inflammatory effects through cytokine-mediated suppression of pathogenic autoimmunity and modulation of microglial activity. This review positions immune modulation as a programmable therapeutic strategy, in which naïve $CD4^+$ T cells (Th0) are actively biased toward a Th2 phenotype through cytokine conditioning and controlled induction of atopic immune signaling. Forced atopy establishes a Type 2–dominant cytokine microenvironment rich in IL-4, IL-10, IL-13, and thymic stromal lymphopoietin (TSLP), thereby suppressing Th1 differentiation, inhibiting IFN-γ–driven neurotoxicity, and reshaping immune–glial crosstalk. Alleamit's patented hyperallergenic platform provides a mechanistically grounded method for inducing sustained Th2 polarization while artificial intelligence–assisted immune monitoring can enhance safety, personalization, and therapeutic precision. Collectively, this framework supports immune reprogramming as a viable disease-modifying strategy in ALS and establishes a foundation for translational development.

Keywords: Amyotrophic Lateral Sclerosis; Artificial Intelligence; Cytokines; Forced Atopy; Immune Modulation; Naïve $CD4^+$ T Cells

1. Introduction

Current ALS therapies focus on modestly slowing disease progression, mitigating excitotoxicity, and managing symptoms rather than addressing the underlying immune mechanisms that contribute to neurodegeneration [1,2]. The growing body of evidence supports ALS as a disease with a significant immunological component, characterized by peripheral immune activation, microglial dysregulation, and pathogenic T-cell polarization [3,10].

Multiple studies demonstrate that Th1- and Th17-skewed immune profiles correlate with accelerated disease progression, increased motor neuron loss, and poorer outcomes in ALS patients [4]. Conversely, Th2-associated immune responses are increasingly recognized for their neuroprotective capacity, mediated through anti-inflammatory cytokines, regulation of microglial phenotype, and suppression of autoimmune cytotoxic pathways [5,6,7,8].

This evolving understanding positions immune modulation—not immune suppression—as a rational therapeutic objective. Specifically, directing naïve $CD4^+$ T cells away from Th1 differentiation and toward a stable Th2 lineage offers a biologically coherent strategy to counteract autoimmune neurotoxicity in ALS.

* Corresponding author: Michael John Dochniak

2. Description

2.1. Th1-Driven Neuroinflammation in ALS

Th1 cells produce interferon-γ (IFN-γ) and promote macrophage and microglial activation toward a neurotoxic, proinflammatory phenotype. Elevated Th1 cytokines have been detected in ALS patient blood, cerebrospinal fluid, and spinal cord tissue, with levels correlating with disease severity and progression [9,10].

Sustained Th1 activation amplifies oxidative stress, glutamate toxicity, and inflammatory microglial signaling—key contributors to motor neuron degeneration. These findings support Th1 dominance not merely as an active contributor to ALS pathology.

2.2. Th2 Cells as Neuroprotective Immune Regulators

Th2 cells secrete IL-4, IL-10, and IL-13, cytokines that suppress Th1 differentiation, inhibit IFN-γ production, and promote alternative (M2-like) microglial activation. In neurodegenerative disease models, Th2 cytokines attenuate inflammatory damage, support neuronal survival, and enhance tissue repair mechanisms [11,12,13,22,23].

In ALS specifically, increased Th2 signaling has been associated with slower disease progression and improved neuronal resilience, supporting a strong association between immune polarization and clinical trajectory [14].

3. Programming Naïve T Cells Through Cytokine Conditioning

3.1. Cytokines That Promote Th2 Differentiation

IL-4 is a principal regulator of Th2 differentiation, acting through STAT6 signaling to induce GATA-3 expression while actively repressing Th1 lineage commitment [15]. Sustained IL-4 exposure not only drives Th2 development but also establishes epigenetic stability of the Th2 phenotype.

IL-10 further reinforces this shift by suppressing antigen-presenting cell activation, downregulating IL-12 production, and inhibiting Th1 and Th17 expansion [16]. Together, IL-4 and IL-10 create a self-reinforcing immune environment that favors Th2 dominance and immune tolerance.

3.2. Cytokines That Inhibit Th1 Pathogenicity

IL-21 has been shown to selectively inhibit Th1 differentiation by suppressing IFN-γ transcription in naïve T cells [17]. Additionally, blockade of IL-17A indirectly suppresses Th1 responses by restoring regulatory T-cell (Treg) function and dampening proinflammatory feedback loops [18].

These cytokine interactions provide multiple leverage points for immune reprogramming rather than deliberate immune suppression.

4. Forced Atopy as a Programmable Immune Modulation Strategy

4.1. Mechanistic Rationale

Forced atopy establishes an immune state with elevated IL-4, IL-5, IL-13, IL-31, and TSLP. IL-4 and IL-13 promote Th2 differentiation, IL-5 enhances eosinophil activation, IL-31 amplifies the overall Th2 response, and TSLP drives Th2 polarization. This cytokine milieu strongly biases naïve T cells toward Th2 differentiation while simultaneously suppressing Th1 and Th17 lineage commitment [19,20].

Importantly, IL-4 and TSLP actively inhibit IL-12 production and IFN-γ signaling, dismantling the molecular architecture required for Th1 persistence [21].

4.2. Neuroimmune Effects of Atopic Signaling

Experimental models demonstrate that allergic immune activation enhances neurogenesis, shifts microglia toward reparative phenotypes, and reduces neuroinflammatory damage [22,23]. These effects directly counteract pathological mechanisms observed in ALS, including chronic microglial activation and oxidative stress.

Alleamit's patented hyperallergenic topical formulations provide a repeatable, titratable, and non-systemic method for inducing sustained Th2-dominant immune signaling, offering a novel route to immune programming without systemic immunosuppression [24].

5. Therapeutic Strategy

5.1. Step 1: Cytokine treatment to promote Th2 expression

• Administration of cytokine treatment includes intravenous (IV) infusion and subcutaneous (SC) injection. The specific administration method, frequency, and dosage depend heavily on the type of cytokine (or cytokine inhibitor) being used and the patient's individual health status.

5.2. Step 2: Sensitization phase

- Topical or transdermal hyperallergenic composition applied over a period to initiate Type-1 hypersensitivity.
- Monitor IgE titers specific to chosen allergens to safely maintain a Type l hypersensitivity.

5.3. Step 3: Evaluation Phase

• Monitor the autoimmune nature of ALS and its prognosis using high precision techniques like flow cytometry, cytokine expression profiling, antigen-specific T cell responses, and neurofilament levels.

6. Artificial Intelligence - Assisted Safety and Precision

Immune modulation requires precise control to avoid excessive allergic responses or immune imbalance. AI-assisted platforms can enable real-time monitoring of cytokine profiles, patient-specific risk stratification, and adaptive dosing strategies. Explainable AI models have already demonstrated utility in ALS monitoring, disease trajectory prediction, and optimization of personalized care [25]. Integrating AI with immune modulation allows for closed-loop safety control, ensuring therapeutic intent while minimizing adverse outcomes.

7. Conclusion

Directed immune modulation through Th2 polarization represents a biologically grounded and mechanistically coherent strategy to counteract autoimmune neurodegeneration in ALS. Cytokine conditioning combined with controlled forced atopy actively suppresses pathogenic Th1 signaling, reshapes microglial behavior, and establishes a neuroprotective immune environment. Alleamit's hyperallergenic platform, augmented by AI-driven safety and personalization, provides a translational pathway for implementing immune programming as a disease-modifying intervention. This approach complements existing ALS therapies while addressing a fundamental driver of disease progression. Advancing this strategy through carefully designed translational studies, right-to-try frameworks, and immune biomarker validation represents a rational and necessary next step.

Compliance with ethical standards

Acknowledgments

Michael John Dochniak (Co-Founder) of Alleamit Corporation, Minnesota, and the United States of America.

Disclosure of conflict of interest

No conflict of interest to be disclosed.

Author Profile

Michael John Dochniak has authored several books on Alzheimer's disease, Artificial Intelligence, Autism Spectrum Disorders, and Climate Change through Cambridge Scholars Publishing and Nova Science Publishers.

References

[1] Gupta D, Vagha S, Dhingra H, Shirsath H. Advances in Understanding and Treating Amyotrophic Lateral Sclerosis (ALS): A Comprehensive Review. Cureus. 2023;15(11).

[2] Tzeplaeff L, Wilfling S, Requardt MV, Herdick M. Current State and Future Directions in the Therapy of ALS. Cells. 2023;12(11):1523.

[3] Michaelis, T., Lindestam Arlehamn, C. S., Johansson, E., Frazier, A., Berry, J. D., Cudkowicz, M., Goyal, N. A., Fournier, C., Snyder, A., Kwan, J. Y., Crook, J., Phillips, E. J., Mallal, S. A., Ravits, J., Marder, K. S., Sidney, J., Sulzer, D., & Sette, A. Autoimmune response to C9orf72 protein in amyotrophic lateral sclerosis. Nature, 2025;647(8091), 970–978.

[4] Jin M, Günther R, Akgün K, Hermann A, Ziemssen T. Peripheral proinflammatory Th1/Th17 immune cell shift is linked to disease severity in amyotrophic lateral sclerosis. Sci Rep. 2020;10(1):5941.

[5] Mackay CR. Follicular homing T helper (Th) cells and the Th1/Th2 paradigm. J Exp Med. 2000;192(11): F31-F34.

[6] Klein B, Mrowetz H, Thalhamer J, Scheiblhofer S, Weiss R, Aigner L. Allergy Enhances Neurogenesis and Modulates Microglial Activation in the Hippocampus. Front Cell Neurosci. 2016; 10:169.

[7] Keegan AD, Leonard WJ, Zhu J. Recent advances in understanding the role of IL-4 signaling. Fac Rev. 2021; 10:71.

[8] Saraiva M, Vieira P, O'Garra A. Biology and therapeutic potential of interleukin-10. J Exp Med. 2020;217(1).

[9] Tau, G. Z., von der Weid, T., Lu, B., Cowan, S., Kvatyuk, M., Pernis, A., Cattoretti, G., Braunstein, N. S., Coffman, R. L., & Rothman, P. B. Interferon gamma signaling alters the function of T helper type 1 cells. J Exp Med. 2000;192(7):977-986.

[10] Zhao W, Beers DR, Appel SH. Immune-mediated mechanisms in the pathoprogression of amyotrophic lateral sclerosis. J Neuroimmune Pharmacol. 2013;8(4):888-899.

[11] Wurster, A. L., Rodgers, V. L., Satoskar, A. R., Whitters, M. J., Young, D. A., Collins, M., & Grusby, M. J. Interleukin 21 is a T helper (Th) cell 2 cytokine that specifically inhibits the differentiation of naive Th cells into interferon gamma-producing Th1 cells. J Exp Med. 2002;196(7):969-977.

[12] Tang, W., Liu, F., Chen, Y., Song, L., Dai, W., Li, C., Weng, D., & Chen, J. Reduction of IL-17A might suppress the Th1 response and promote the Th2 response by boosting the function of Treg cells during silica-induced inflammatory response in vitro. Mediators Inflamm. 2014; 2014:570894.

[13] Ogulur I, Mitamura Y, Yazici D, Pat Y, Ardicli S, Li M, D'Avino P, Beha C, Babayev H, Zhao B, Zeyneloglu C, Giannelli Viscardi O, Ardicli O, Kiykim A, Garcia-Sanchez A, Lopez JF, Shi LL, Yang M, Schneider SR, Skolnick S, Dhir R, Radzikowska U, Kulkarni AJ, Imam MB, Veen WV, Sokolowska M, Martin-Fontecha M, Palomares O, Nadeau KC, Akdis M, Akdis CA.. Type 2 immunity in allergic diseases. Cell Mol Immunol. 2025;22(3):211-242.

[14] Beers DR, Zhao W, Wang J, Zhang X, Wen S, Neal D, Thonhoff JR, Alsuliman AS, Shpall EJ, Rezvani K, Appel SH. ALS patients' regulatory T lymphocytes are dysfunctional, and correlate with disease progression rate and severity. JCI Insight. 2017;2(5).

[15] Zhu J. T helper 2 (Th2) cell differentiation, type 2 innate lymphoid cell (ILC2) development and regulation of interleukin-4 (IL-4) and IL-13 production. Cytokine. 2015;75(1):14-24.

[16] O'Garra A, Vieira P. Regulatory T cells and mechanisms of immune system control. Nat Med. 2004;10(8):801-805.

[17] Spolski R, Leonard WJ. IL-21 and T follicular helper cells. Int Immunol. 2010;22(1):7-12.

[18] Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 Cells. Annu Rev Immunol. 2009; 27:485-517.

[19] Paul, W., Zhu, J. How are TH2-type immune responses initiated and amplified? Nat Rev Immunol. 2010;10, 225–235.

[20] Ziegler, S. F., & Artis, D. Sensing the outside world: TSLP regulates barrier immunity. Nature immunology. 2010; 11(4), 289–293.

[21] Szabo SJ, Kim ST, Costa GL, Zhang X, Fathman CG, Glimcher LH. A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell. 2000;100(6):655-669.

[22] Kipnis J. Multifaceted interactions between adaptive immunity and the central nervous system. Science. 2016;353(6301):766-771.

[23] Schwartz M, Deczkowska A. Neurological Disease as a Failure of Brain-Immune Crosstalk: The Multiple Faces of Neuroinflammation. Trends Immunol. 2016;37(10):668-679.

[24] Dochniak MJ. Topical hyper-allergenic composition and method of treating using the same. USPTO 11,911,463. 02/27/2024.

[25] Ga Hoghooghi Esfahani H, Toyonaga S, Oyibo K. The application of explainable artificial intelligence in the prediction, diagnoses, treatment, and management of chronic diseases: A systematic review. Digit Health. 2025;11:20552076251355669.